Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17535855 | 0.80 | HTT (0.45) | KDM4EALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL16056078 | 0.78 | ALDH1A1 (0.43) | KDM4EALDH1A1KMT2AL3MBTL1MAPT | |
| SCHEMBL16055545 | 0.77 | ALDH1A1 (0.45) | KDM4EALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL16616028 | 0.76 | POLB (0.43) | KDM4EALDH1A1KMT2AL3MBTL1MAPT | |
| SCHEMBL16056140 | 0.76 | KDM4E (0.55) | KDM4EALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL16055755 | 0.74 | ALDH1A1 (0.45) | KDM4EALDH1A1ALDH1A3KMT2AL3MBTL1 | |
| SCHEMBL2962020 | 0.73 | ALDH1A1 (0.50) | KDM4EALDH1A1KMT2AL3MBTL1MAPT | |
| SCHEMBL2963966 | 0.73 | ALDH1A1 (0.58) | KDM4EALDH1A1KMT2AL3MBTL1MAPT | |
| SCHEMBL16055692 | 0.72 | ALDH1A1 (0.49) | KDM4EALDH1A1KMT2AL3MBTL1MAPT | |
| SCHEMBL16616036 | 0.72 | ALDH1A1 (0.41) | KDM4EALDH1A1L3MBTL1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | KDM4E 3566/4885ALDH1A1 2449/4885ALDH1A3 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.